{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T22:58:12Z","timestamp":1771023492040,"version":"3.50.1"},"reference-count":33,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T00:00:00Z","timestamp":1713139200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Vet Comparative Oncology"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Canine carcinomatosis (CC) and mesothelioma (CM) are rare but aggressive neoplasms that historically have been associated with poor prognoses. There is limited information regarding treatment for CC and CM. The purpose of this retrospective study was to evaluate the efficacy and tolerability of toceranib phosphate (Palladia) in dogs with CC and CM. Cases were solicited from the American College of Veterinary Internal Medicine (ACVIM) Oncology listserv and retrospectively reviewed. For eligibility, a cytologic and\/or histopathologic diagnosis of CC or CM was required. A total of 23 cases were included (CC\u2009=\u200914, CM\u2009=\u20098, both\u2009=\u20091). Eighty\u2010two percent (19\/23) of dogs presented with effusion. The best overall response rate (BORR) was 30.4% (13% complete response [CR], 17.3% partial response [PR]). Stable disease (SD) was appreciated in 14 dogs (60.8%) including the four dogs without effusion. The most common toceranib\u2010related adverse events were either Grade 1 and 2 diarrhea or hyporexia. The median progression\u2010free survival (PFS) was 171\u2009days (range, 7\u2013519\u2009days) and overall median survival time (MST) was 301\u2009days (range, 49\u2013875\u2009days) for all dogs. When evaluating dogs solely with effusion, the median PFS and overall MST were 171 days (range, 7\u2013519 days) and 285 days (range, 49\u2013875 days), respectively. This report demonstrates that toceranib is both well tolerated and a potential treatment for CC and CM. A randomised, controlled, prospective study would be needed to objectively assess the survival benefit of toceranib in the management of CC and CM, with and without effusion.<\/jats:p>","DOI":"10.1111\/vco.12972","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T02:33:18Z","timestamp":1713234798000},"page":"245-254","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Retrospective evaluation of toceranib phosphate (Palladia) in the treatment of canine carcinomatosis and mesothelioma"],"prefix":"10.1111","volume":"22","author":[{"given":"Kelly A.","family":"Hicks","sequence":"first","affiliation":[{"name":"Carlson College of Veterinary Medicine Oregon State University  Corvallis Oregon USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0900-0851","authenticated-orcid":false,"given":"Haley J.","family":"Leeper","sequence":"additional","affiliation":[{"name":"Carlson College of Veterinary Medicine Oregon State University  Corvallis Oregon USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaitlin M.","family":"Curran","sequence":"additional","affiliation":[{"name":"Carlson College of Veterinary Medicine Oregon State University  Corvallis Oregon USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,4,15]]},"reference":[{"key":"e_1_2_8_2_1","first-page":"553","volume-title":"Veterinary cancer medicine","author":"Theilen G","year":"1987"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.5772\/31830"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939\u2010165x.1999.tb01065.x"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/jsap.12830"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/vcp.13002"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.2478\/pjvs\u20102014\u20100020"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12917\u2010023\u201003655\u20108"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/vco.12843"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/vco.12777"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1292\/jvms.69.201"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476\u20105810.2005.00075.x"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939\u20101676.1991.tb00953.x"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/vco.12426"},{"issue":"5","key":"e_1_2_8_15_1","first-page":"493","article-title":"Ovarian carcinomatosis in a dog managed with surgery and intraperitoneal, systemic, and intrapleural chemotherapy utilizing indwelling pleural access ports","volume":"58","author":"Best MP","year":"2017","journal-title":"Can Vet J"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939\u20101676.2002.tb02349.x"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990101)85:1<178::AID-CNCR25>3.0.CO;2-7"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.824"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2010.10.010"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.21037\/apm\u201021\u20102623"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(15)01238\u20106"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476\u20105829.2011.00275.x"},{"issue":"7","key":"e_1_2_8_23_1","first-page":"2755","article-title":"Phase I dose\u2010escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies","volume":"9","author":"London CA","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/vco.12677"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1354\/vp.43\u20102\u2010198"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/104063870802000525"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/vcp.12394"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/vco.12032"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/1746\u20106148\u20109\u2010190"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201008\u20101860"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.239.8.1084"},{"key":"e_1_2_8_32_1","first-page":"356","article-title":"Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer","volume":"62","author":"Mohammed SI","year":"2002","journal-title":"Cancer Res"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939\u20101676.1994.tb03232.x"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvim.12013"}],"container-title":["Veterinary and Comparative Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vco.12972","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T03:15:47Z","timestamp":1715310947000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vco.12972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,15]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1111\/vco.12972"],"URL":"https:\/\/doi.org\/10.1111\/vco.12972","archive":["Portico"],"relation":{},"ISSN":["1476-5810","1476-5829"],"issn-type":[{"value":"1476-5810","type":"print"},{"value":"1476-5829","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,15]]},"assertion":[{"value":"2023-11-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}